Please discuss how the applied concentrations are related to the clinically used dosage (75 mg administered orally twice https://clinicaltrials.gov/ct2/show/NCT02448290) and why not the more efficient MEK1 inhibitor trametinib was used for the experiments.
However, cell proliferation was analyzed only in a 24-hour long period even though most cancer cells have a doubling time around 24 hours.